What is the appropriate management for a 71-year-old woman with type 2 diabetes, severe hyperglycemia (blood glucose 460 mg/dL), modest ketoacidosis (ketones 5.23 mmol/L, anion gap 20 mmol/L, bicarbonate 22 mmol/L, venous pH 7.35), high serum osmolarity (315 mOsm/kg), creatinine 0.99 mg/dL, eGFR 61 mL/min/1.73 m², history of pancreatitis and alcohol use, currently taking glipizide, and hemoglobin A1c 13.1%?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Immediate Management: Hospitalize for Acute Hyperglycemic Crisis with Ketosis

This patient requires immediate hospitalization for treatment of a hyperglycemic crisis with significant ketosis—she presents with severe hyperglycemia (BG 460 mg/dL), elevated ketones (5.23 mmol/L), high anion gap (20 mmol/L), and hyperosmolarity (315 mOsm/kg), representing an overlap syndrome between diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS). 1, 2

Acute Inpatient Management

Initial Treatment Protocol

Start intravenous insulin infusion immediately to suppress ketogenesis and correct hyperglycemia, combined with aggressive fluid resuscitation 1, 2. The venous pH of 7.35 with bicarbonate 22 mmol/L indicates she is on the milder end of the acidosis spectrum, but the elevated ketones (5.23 mmol/L) and anion gap (20 mmol/L) confirm active ketoacidosis requiring insulin therapy.

Key treatment steps:

  • Fluid resuscitation: Restore circulatory volume and tissue perfusion with IV normal saline
  • Continuous IV insulin: Standard of care for hyperglycemic crisis with ketosis 1, 2
  • Monitor blood glucose every 2-4 hours: Add dextrose to IV fluids once glucose falls to 250 mg/dL to prevent hypoglycemia while continuing insulin to clear ketones 2
  • Electrolyte monitoring and replacement: Particularly potassium—expect total body depletion despite normal initial levels 1
  • Identify precipitating factors: Evaluate for infection, cardiac events, or other acute illness 1, 2

Critical Pitfall: Don't Stop Insulin Too Early

Continue IV insulin until the anion gap normalizes and ketones clear, not just until glucose normalizes 1, 2. Premature discontinuation will allow ketogenesis to resume. When transitioning from IV to subcutaneous insulin, administer basal insulin 2-4 hours before stopping the IV infusion to prevent rebound hyperglycemia and recurrent ketoacidosis 1, 2.

Discharge Planning and Long-Term Management

Discontinue Glipizide Immediately

Glipizide must be discontinued 3. This sulfonylurea is contraindicated in her current state and inappropriate for long-term management given:

  • Her history of pancreatitis (glipizide can cause severe hypoglycemia in stressed states) 3
  • Her severe hyperglycemia (A1c 13.1%) indicating complete therapeutic failure
  • Her age (71 years) and reduced kidney function (eGFR 61 mL/min) increase hypoglycemia risk 3

Insulin Therapy at Discharge

Initiate basal-bolus insulin regimen given the severity of hyperglycemia (A1c 13.1%) and acute presentation with ketosis 4. The 2022 ADA/EASD consensus specifically states insulin is preferred when HbA1c >10% (86 mmol/mol), particularly when associated with ketosis 4.

Recommended insulin regimen:

  • Basal insulin (glargine, detemir, or degludec): Start at 0.2-0.3 units/kg/day = approximately 15-22 units daily for her 74 kg weight 4, 5
  • Prandial rapid-acting insulin (lispro, aspart, or glulisine): Start with largest meal, typically 4-6 units before each meal 6
  • Teach self-titration: increase basal by 2 units every 3 days if fasting glucose remains >130 mg/dL 6

Add Metformin Once Stable

Start metformin 500 mg twice daily (with meals) once she is eating normally and metabolically stable, increasing to 1000 mg twice daily as tolerated 4. Her eGFR of 61 mL/min allows metformin use, though monitor kidney function given her age 4.

Consider GLP-1 Receptor Agonist

Add a GLP-1 receptor agonist (e.g., semaglutide, dulaglutide) once insulin is established and she is metabolically stable 4. The 2022 ADA/EASD consensus emphasizes GLP-1 RA should be considered before intensifying insulin therapy in most patients, but given her acute presentation with ketosis, insulin takes priority initially 4. GLP-1 RA will help reduce insulin requirements, promote weight loss, and provide cardiovascular protection 4.

Age-Appropriate Glycemic Targets

For this 71-year-old with multiple comorbidities (pancreatitis history, alcohol use, CKD stage 3a), target A1c of 7.5-8.0% is appropriate rather than <7% 6, 7. The 2012 ADA/EASD position statement specifically recommends less stringent targets for older adults with comorbidities to minimize hypoglycemia risk, which can cause falls, fractures, and cardiovascular events in this population 6, 7.

Monitoring and Follow-up

  • Diabetes self-management education before discharge 2
  • Outpatient follow-up within 1 week with primary care or endocrinology 2
  • Daily self-monitoring of blood glucose at minimum: fasting and before meals 6
  • Consider continuous glucose monitoring given insulin therapy 4
  • Reassess kidney function in 3 months given borderline eGFR 4
  • Screen for cardiovascular disease and consider cardioprotective agents once stable 4

Address Alcohol Use

Her history of pancreatitis with alcohol use requires attention. Alcohol can precipitate both hypoglycemia (by impairing gluconeogenesis) and ketoacidosis (through starvation ketosis), and increases risk of recurrent pancreatitis 3. Counsel on alcohol cessation and consider referral to addiction services.

References

5
Guideline

management of diabetes and hyperglycaemia in the hospital.

The Lancet Diabetes and Endocrinology, 2021

Related Questions

What is the appropriate initial management for a patient with diabetic ketoacidosis (glucose 427 mg/dL, serum sodium 127 mmol/L, CO₂ 18 mmol/L, anion gap 14, beta‑hydroxybutyrate 2.03 mmol/L)?
Should a 52-year-old woman with type 2 diabetes who was admitted for diabetic ketoacidosis, now has a closed anion gap, and is on metformin 850 mg twice daily plus basal insulin glargine 10 units daily, have her metformin dose increased, continue the current insulin regimen, or add a thiazolidinedione?
A 71-year-old female with type 2 diabetes mellitus, weight 74 kg, normal creatinine, moderately reduced estimated glomerular filtration rate, elevated anion gap, low bicarbonate, severe hyperglycemia, elevated serum ketones, mild acidosis, high serum osmolality, history of pancreatitis, currently taking glipizide only, and hemoglobin A1c rising from 6.8% to 13.1%—what is the appropriate management?
What is the appropriate emergency management for a 54-year-old male with uncontrolled diabetes, blood glucose 365 mg/dL, four days of dizziness, nausea, vomiting, and who has missed insulin and GLP‑1 therapy for one week?
In a 68-year-old patient presenting with weakness, visual disturbances, confusion, severe hyperglycemia, mild metabolic acidosis, weakly positive urinary acetone, and a normal anion gap, which of the following statements is false?
In a 6‑year‑4‑month‑old girl with a strong familial pattern of hirsutism, can early isolated pubic hair (Tanner stage P1) be a normal variant, and what endocrine evaluation and monitoring are recommended?
A 71-year-old female with type 2 diabetes mellitus, weight 74 kg, normal creatinine, moderately reduced estimated glomerular filtration rate, elevated anion gap, low bicarbonate, severe hyperglycemia, elevated serum ketones, mild acidosis, high serum osmolality, history of pancreatitis, currently taking glipizide only, and hemoglobin A1c rising from 6.8% to 13.1%—what is the appropriate management?
What is the appropriate treatment for a spider bite?
Can you calculate the BMI for a girl who is 131.5 cm tall and weighs 27.5 kg?
What long‑term side effects and adverse effects can result from combining an etonogestrel implant (Implanon) with continuous norethisterone acetate (Primolut) to achieve amenorrhea in a non‑binary adolescent transgender patient with catamenial dysphoria?
What lorazepam dose should be used in a patient already receiving olanzapine (Zyprexa) 10 mg daily?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.